David Robert Norwood

Part of Investec Plc, IndexIT Partnership is a British company that provides information technology consulting services. The private company is based in Oxford, UK. The company was founded by David Robert Norwood. IndexIT Partnership was acquired by Beeson Gregory Group Plc on February 04, 2000.

BenevolentAI Cambridge Ltd. develops novel small molecule therapeutics, in particular in the areas of CNS, pain and inflammation. It specializes in drug development, project management and translational medicine. The company was founded on November 26, 2003 and is headquartered in London, the United Kingdom.

Ilika Technologies Ltd is a privately held company which was spun out of the University of Southampton in May 2004. Ilika quickly established a reputation for innovation, revenue generation and profitability in the high growth industry of materials development. As a result, the company has attracted investment from blue chip investors who have provided the resources necessary to support the rapid growth of the company. Although many industries are addressable through the company's high throughput technology, Ilika has chosen to focus upon the energy, electronics and biomedical sectors. The company's technology and discovered materials are protected through worldwide patent applications. Ilika engages with customers through research collaborations and through the licensing of materials which Ilika has developed for different applications.

Part of Baron Oil Plc, Plectrum Petroleum Plc is a British company that explores for oil and natural gas offshore. The private company is based in Banchory, UK. The company was founded by David Robert Norwood, Michael Whyatt. Plectrum Petroleum was acquired by Gold Oil Caribbean Ltd. from Capricorn Energy Plc on October 13, 2008.

DeepMatter Group Plc is engaged in the development of a number of projects targeting new chemicals, materials, formulations, and pharmaceuticals in commercial areas. It operates through the following segments: DeepMatter and InfoChem. The DeepMatter segment owns, develops and is in the early stage of exploiting intellectual property, software, hardware and data analysis capabilities combined as a visionary, disruptive platform called DigitalGlassware, enabling step changes in productivity and discovery for scientists in the pharma and life science sectors. The InfoChem segment develops and commercialises cheminformatics software to handle, store and retrieve chemical structures and reactions for application in pharma, life sciences, and scientific publications. The company was founded by Jon-Paul Griffiths and Mark G. Moloney on June 13, 2006 and is headquartered in Glasgow, the United Kingdom.

Part of Velocys Plc, Velocys Technologies Ltd. is a British company that provides high-performance catalyst and reactor technology to generate negative-carbon-emissions SAF with the integration of carbon capture technologies. The private company is based in Harwell, UK and was founded in 2004 by David Robert Norwood. The company enables sustainable, net negative carbon emissions fuel to be produced safely and effectively on a commercial scale. Velocys provides its customers with the technology to enable production of negative carbon intensity, drop-in fuels from a variety of waste materials.

Abaco Capital Plc was a drug development company, which was engaged in re-developing approved drugs using proprietary formulation technologies. The company was founded by Marcelo Bravo and Nigel Theobald on October 7, 2009 and was headquartered in London, the United Kingdom.

Part of hVIVO PLC, hVIVO Services Ltd. is a British company that specializes in full-service viral challenge studies. The private company is based in London, UK. The company's services include challenge models and lab services. The company was founded in 1988 by John Sidney Oxford.

Genomics Plc develops research and experimental development on biotechnology. It develops and applies cutting edge analysis and algorithms to database of genomic and phenotypic data to uncover the relationships between genetic variation and human disease. The company was founded by Peter Donnely, Gil McVean, Chris Spencer and Gerton Lunter on January 10, 2004 and is headquartered in Oxford, the United Kingdom.